Improving patient outcomes through collaboration

The return on R&D investments in the UK is at its lowest rate in nine years, despite Britain’s global presence in science, technology and health. Pharmaceutical attrition rates continue to rise, and the UK biotech landscape remains fragmented. Medicines Discovery Catapult (MDC) aims to connect the UK R&D community more effectively by putting the patient at the heart of the drug discovery process. As part of our collaboration with the MDC, REPROCELL have pledged to provide custom drug discovery assays using live human tissues.

Continue reading 

Using human iPSCs as an in vitro model for regenerative medicine, drug screening and disease modelling

In translational medicine, research using primary patient samples is advantageous over cell lines as the expression of the protein under investigation is regulated by native elements in primary samples.

Continue reading 

TISSUE SPOTLIGHT: Skin

In this issue, we are casting the REPROCELL Tissue Spotlight on the SKIN.

In humans, the largest organ in the body is the skin layer, accounting for up to 15% of the total body weight and a surface area of up to 2m2. It is composed of several layers — the epidermis, dermis and the sub-cutaneous layer, the hypodermis — each crucial to the many functions of the skin ranging from a protective barrier for internal tissues and organs, through regulation of body temperature and nutrient absorption, to the generation of vitamin D.

Continue reading 

TISSUE SPOTLIGHT: Intestines

In this issue, we are casting the REPROCELL Tissue Spotlight on the INTESTINES.

The intestines (large and small) are vital organs in the gastrointestinal tract of our digestive system. Comprising a winding muscular tube extending from the stomach to the anus the main purpose is to digest food and absorb nutrients. The intestines also have a key role to play in the processes of cellular messaging, fighting infection and in regulating the body’s water balance.

Continue reading 

The Human Touch: meeting clinical needs in IBD research

There is a clinical need for novel therapies in Inflammatory Bowel Disease. Current research is however limited by models which do not physiologically mimic the disease in humans. REPROCELL’s Human IBD Fresh Tissue Assay is the most clinically relevant IBD model on the market and the only commercially available assay of its kind.

Continue reading 

Human Tissue Experts REPROCELL Launch New Customized Primary Cell Isolation Services

REPROCELL’s BioServe and Biopta tissue procurement networks combine to create a new service isolating human primary cells.

Continue reading 

Characterization of iPSCs by Immunocytochemistry

As part of our contract services at REPROCELL, we offer induced pluripotent stem cell (iPSC) characterization by immunocytochemistry (ICC). Planning ICC can be tricky, as it requires careful selection of compatible antibodies and fluorochromes. However, if successful, the results are fantastic! Don’t waste valuable research time performing ICC, and let our experts do the work for you!

Continue reading 

The Benefits of Human Tissue to Drug Discovery and Development

Progressive and innovative Pharmaceutical and Biotechnology companies ask themselves several key questions when it comes to Drug Discovery and Development:

• How and where can we be research smarter? 
• How can we reduce uncertainty? 
• How can we better predict efficacy and safety? 
• How can we reduce costs?

One route to making the drug discovery process smarter and more efficient is to use human tissue at one or more stages in the development process.

Continue reading 

REPROCELL’s David Bunton addresses the Scottish Parliament

On Tuesday 20th March 2018 REPROCELL Europe Ltd’s CEO Dr David Bunton appeared in front of the Economy, Jobs and Fair Work Committee at the Scottish Parliament to discuss Scotland’s Economic performance.  He was also joined by:

• Dr Diane Harbison, CEO, of Stratified Medicine Scotland

• Claire Mack, CEO, of Scottish Renewables

• Gareth Wynn, Stakeholder and Communications Director, Oil & Gas UK

Continue reading 

Patient-derived tumor organoids recapitulated clinical treatments

The pharmaceutical industry suffers from very high rates of clinical failure, because preclinical predictions of efficacy often fail to realize a clinical benefit. In part, this can be attributed to an over-reliance on animal models of efficacy, which often do not fully predict human responses to drugs. Two areas where very few predictive models are available is inflammatory bowel disease (IBD)—which includes ulcerative colitis and Crohn’s disease—and gastrointestinal cancer—specifically cancer of the small intestine and the colon. REPROCELL has set out to solve these challenges by developing new preclinical tests based on human tissues.

Continue reading